GlobeNewswire EN Nachrichten

 

To Nasdaq OMX Copenhagen A/S...

OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study) (see: ClinicalTrials.gov NCT05927142)....

Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics...

Capgemini today announced a new strategic partnership with OpenAI to accelerate the next era of enterprise AI transformation with Frontier....

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to update shareholders on exploration drilling by Cartier Resources Inc. (ECR-TSXV, 6CA-FSE) on Globex's Nordeau Royalty claims (Exhibit 1) in Vauquelin Township (32C03), 45 km southeast of Val d'Or, Quebec. Globex holds a 3% Gross Metal Royalty on the Nordeau claims including the area where Cartier has identified a new gold zone called the East Nordeau Zone on Cartier's Cadillac Property. Late last year Cartier embarked on an aggressive 600 drill hole, 100,000 metre drill program on its Cadillac property....

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days...

Initial Contract Establishes New $250,000 Annual Recurring Revenue (ARR) Stream With Expansion Potential Exceeding $1 Million...

Announcement...

FUKUOKA, Japan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) ("rYojbaba" or the "Company"), a Japanese consulting and health services company, collaborated with Guardian Girls USA and United Nations Population Fund (“UNFPA”) to launch the Guardian Girls Aikido (“GGA”) project at the Terasaki Budokan in downtown Los Angeles, California....

NEENAH, WI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Plexus Corp. (NASDAQ: PLXS) announced today that it will attend the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on March 2, 2026. During the conference, Raymond James will host a fireside chat with Plexus' management team at 10:25 a.m. Eastern Time. The fireside chat will be available via live webcast....

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework...

New program off to a successful start with 3.96% average monthly yield after first four weeks New program off to a successful start with 3.96% average monthly yield after first four weeks...

Top-tier Anheuser-Busch network distribution partner Jefferson Distributing (WV) adds critical “footprint fill-in” coverage as American Rebel continues rapid national expansion with sustained execution of its Distribution-First strategy...

FORT LAUDERDALE, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- OptimumBank Holdings, Inc. (NYSE American: OPHC) (“Company”) announced today the formation of OptimumFunding, LLC (“OptimumFunding”), a wholly owned subsidiary created to support a new HUD and FHA lending initiative, representing a significant milestone in the Company's long-term strategic growth plan....

PDUFA action date set for August 23, 2026...

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for gross proceeds of $205 million upon the closing of the transaction....

PharmAla to supply University of Amsterdam with LaNeo MDMA for a clinical trial, generating new stability data for blister packs in the process...

Satellogic Launches Aleph Observer, a Persistent Global Intelligence Capability Designed for Sustained Awareness at Scale...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that company leadership will participate in multiple upcoming investor conferences....

Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04...